Chetan V. Vakkalagadda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chetan V. Vakkalagadda has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andy Kaempf
Cancer Data Science Shared Resource OHSU, Knight Cancer Institute Portland Oregon USA
1 shared publication - Avanthi Ragam
Northwestern Medicine Delnor Hospital, Geneva, IL 60134, USA
1 shared publication - Cameron Chalker
Division of Hematology and Medical Oncology Oregon Health & Science University (OHSU), Knight Cancer Institute Portland Oregon USA
1 shared publication - Danielle B. Dressler
Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
1 shared publication - Eric Roeland
Oregon Health and Science University
1 shared publication Erynn A. Beeson
Division of Palliative Medicine University of California San Francisco San Francisco California USA
1 shared publication
Latest Publications
- 23 October 2026
- Published by Wiley in Head & Neck
Exploring G‐Tube Timing and Clinical Outcomes in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Chemoradiation
Background: G‐tube placement timing remains poorly characterized in patients with localized head and neck cancer (HNSCC) undergoing definitive chemoradiation (dCRT). Methods: We retrospectively analyzed 144 patients with HNSCC who received dCRT (2019–2024), categorized by “upfront” or “as‐needed” G‐tube strategy, to explore factors associated with timing and outcomes using propensity score weighting. Results: Most patients were White (85%) and male (83%); median age was 63 years. Upfront G‐tube placement occurred in 60 patients (42%) and was more common among women (64% vs. 37%, p = 0.015) and those with dysphagia (55% vs. 28%, p = 0.001) or receiving induction chemotherapy (71% vs. 38%, p = 0.023). dCRT duration, weight loss, ED visits, hospitalizations, ICU admissions, and survival did not differ. Upfront placement was associated with lower odds of chemotherapy modification (73% lower, p = 0.007) and fewer infusion clinic visits (average 3 fewer, p = 0.038). Conclusion: These findings suggest multiple factors influence G‐tube timing and outcomes, warranting prospective validation.
- 23 October 2026
- Published by Wiley in Head & Neck
Exploring G‐Tube Timing and Clinical Outcomes in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Chemoradiation
Background: G‐tube placement timing remains poorly characterized in patients with localized head and neck cancer (HNSCC) undergoing definitive chemoradiation (dCRT). Methods: We retrospectively analyzed 144 patients with HNSCC who received dCRT (2019–2024), categorized by “upfront” or “as‐needed” G‐tube strategy, to explore factors associated with timing and outcomes using propensity score weighting. Results: Most patients were White (85%) and male (83%); median age was 63 years. Upfront G‐tube placement occurred in 60 patients (42%) and was more common among women (64% vs. 37%, p = 0.015) and those with dysphagia (55% vs. 28%, p = 0.001) or receiving induction chemotherapy (71% vs. 38%, p = 0.023). dCRT duration, weight loss, ED visits, hospitalizations, ICU admissions, and survival did not differ. Upfront placement was associated with lower odds of chemotherapy modification (73% lower, p = 0.007) and fewer infusion clinic visits (average 3 fewer, p = 0.038). Conclusion: These findings suggest multiple factors influence G‐tube timing and outcomes, warranting prospective validation.
- 5 August 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (7) , e591-e598.e1
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer
- 5 August 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (7) , e591-e598.e1
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer
- Open Access
The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System
Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.
Open AccessThe Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System
Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.
- Open Access
- 15 November 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (12) , 100603
Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report
- 15 November 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (12) , 100603
Open AccessAddition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report